Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from OS Therapies Incorporated ( (OSTX) ).
On March 31, 2026, OS Therapies Incorporated filed a prospectus supplement with the U.S. Securities and Exchange Commission as part of an existing Form S-3 shelf registration that had been declared effective in August 2025. The supplement registers the potential resale from time to time of up to 10,529,417 shares of common stock by certain selling stockholders, reflecting a step that may enhance liquidity for existing holders without directly raising new capital for the company.
In connection with this capital markets move, OS Therapies submitted a Current Report on Form 8-K to provide the legal opinion of its counsel, Olshan Frome Wolosky LLP, on the validity of the registered shares. This legal confirmation supports the regulatory compliance of the offering framework and helps facilitate secondary-market transactions by the selling stockholders under the shelf registration.
The most recent analyst rating on (OSTX) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.
Spark’s Take on OSTX Stock
According to Spark, TipRanks’ AI Analyst, OSTX is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, widening losses and higher 2025 cash burn) and a bearish technical setup (below major moving averages). Recent positive financing activity supports liquidity and offsets some risk, but dilution/financing dependence remains a key overhang, while valuation signals continued losses with no dividend support.
To see Spark’s full report on OSTX stock, click here.
More about OS Therapies Incorporated
OS Therapies Incorporated operates in the biopharmaceutical sector, focusing on the development of therapeutic products, though this filing primarily reflects its capital markets activities rather than specific drug programs. The company accesses public equity markets through SEC-registered offerings of its common stock to support its corporate and development objectives.
Average Trading Volume: 575,737
Technical Sentiment Signal: Sell
Current Market Cap: $46.84M
For a thorough assessment of OSTX stock, go to TipRanks’ Stock Analysis page.